2-Diphenylmethylpyrrolidine, also known as Desoxy-D2PM or 2-benzhydrylpyrrolidine, is a psychoactive stimulant drug. This compound is a structural analogue of diphenylprolinol (D2PM) with the removal of the hydroxyl group, and it shares structural similarities with desoxypipradrol (2-DPMP). Both D2PM and 2-DPMP function as norepinephrine-dopamine reuptake inhibitors (NDRIs). Desoxy-D2PM has been marketed and used as a designer drug, sometimes found in the production of legal highs. Its street names include A3A New Generation, A3A Methano, and Green Powder. Users have reported experiencing hallucinations, aggressive behaviour, dilated pupils, tachycardia, and high blood pressure when using Desoxy-D2PM. Literature data suggest that it can induce psychotropic effects similar to other stimulants but with a longer duration of action.
Desoxy-D2PM consists of two enantiomers, which find industrial use in their purified form as chiral derivatizing agents during chemical synthesis.
On November 4, 2010, the UK Home Office initiated a ban on the importation of 2-diphenylmethylpyrrolidine following a recommendation from the ACMD (Advisory Council on the Misuse of Drugs). It was slated to be categorized as a class B drug on March 28, 2012; however, the bill was eventually scrapped due to the inclusion of two steroids that were later suggested to remain uncontrolled. Ultimately, on June 13, 2012, Desoxy-D2PM was classified as a class B drug and placed in Schedule I.
|CompTox Dashboard (EPA)||DTXSID80922897|
|Chemical and physical data|
|Molar mass||237.339 g·mol−1|
1. What is 2-Diphenylmethylpyrrolidine (Desoxy-D2PM)? 2-Diphenylmethylpyrrolidine, also known as Desoxy-D2PM or 2-benzhydrylpyrrolidine, is a psychoactive stimulant drug with structural similarities to other substances like D2PM and 2-DPMP. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI).
2. What are the common street names for Desoxy-D2PM? This compound has been marketed and sold under various street names, including A3A New Generation, A3A Methano, and Green Powder.
3. What effects are associated with Desoxy-D2PM use? Users have reported experiencing a range of effects, including hallucinations, aggressive behaviour, dilated pupils, tachycardia (rapid heartbeat), and high blood pressure when using Desoxy-D2PM. It is known for inducing psychotropic effects similar to other stimulants but with a longer duration of action.
4. How is Desoxy-D2PM used? Desoxy-D2PM has been used recreationally and has been found in designer drugs and legal highs. It is typically ingested, but the specific methods of use may vary among individuals.
5. Are there different forms or enantiomers of Desoxy-D2PM? Yes, Desoxy-D2PM exists in two enantiomers, and these purified forms are used industrially as chiral derivatizing agents during chemical synthesis.
6. What is the legal status of Desoxy-D2PM? The legal status of Desoxy-D2PM varies by country and region. In some places, it has been classified as a controlled substance due to its psychoactive properties. Always be aware of and comply with local laws and regulations regarding its possession and use.
7. Has Desoxy-D2PM been banned in any country? Yes, in the United Kingdom, for example, the importation of 2-diphenylmethylpyrrolidine was banned in 2010, and it was eventually classified as a class B drug and placed in Schedule I on June 13, 2012.
8. Are there any known medical uses for Desoxy-D2PM? As of my last knowledge update in September 2021, Desoxy-D2PM does not have recognized medical applications. It is primarily known for its recreational use. Consult with healthcare professionals for the most up-to-date information on any substance.
9. What should I do if I have questions or concerns about Desoxy-D2PM? Suppose you have questions or concerns about Desoxy-D2PM. In that case, it is advisable to seek guidance from medical professionals, toxicologists, or relevant authorities who can provide accurate and up-to-date information and advice on its use and risks.
- De Paoli G, Brandt SD, Pounder DJ (December 2011): This December 2011 study discusses the analytical characterization and rapid determination of 2-(diphenylmethyl)pyrrolidine in blood. It also highlights the application of these findings to an internet product, shedding light on the identification of this compound in biological samples.
- “2-(Diphenylmethyl)pyrrolidine (desoxy-D2PM)” (in Italian): An Italian source from the Dipartimento Politiche Antidroga in Rome provides information about 2-(diphenylmethyl)pyrrolidine (desoxy-D2PM). This source likely contains details about the compound and its properties.
- DC Shanie Nayar. “Green Powder called A3A Methano” (PDF): This document, attributed to DC Shanie Nayar, likely discusses a product known as “Green Powder” and its association with A3A Methano. It may contain information about the composition and effects of this substance.
- Coppola M, Mondola R (July 2012): In July 2012, a study by Coppola and Mondola addresses research chemicals marketed as legal highs, with a specific focus on pipradrol derivatives. This study may provide insights into the use and effects of such substances.
- Bertelsen S, Halland N, Bachmann S, Marigo M, Braunton A, Jørgensen KA (October 2005): This October 2005 publication discusses organocatalytic asymmetric alpha-bromination of aldehydes and ketones. While not directly related to 2-(diphenylmethyl)pyrrolidine, it may contain information on chemical reactions and processes relevant to the compound’s synthesis.
- Import ban on psychoactive drug: This source likely pertains to the UK Home Office’s decision to impose an import ban on a psychoactive drug. It could provide insights into the regulatory actions taken against certain substances.
- “The Misuse of Drugs Act 1971 (Amendment) Order 2012” (PDF): Dated January 27, 2012, this document from the UK Home Office discusses amendments to the Misuse of Drugs Act 1971. It may contain information regarding the legal classification of specific substances.
- “Government accepts ACMD’s advice to schedule D2PM, 2-DPMP and phenzepam” (PDF): This January 27, 2012 document from the UK Home Office discusses the government’s acceptance of the Advisory Council on the Misuse of Drugs (ACMD) advice regarding the scheduling of certain substances, including D2PM and 2-DPMP.
- “ACMD letter on further advice on the classification of two steroidal substances – February 2012” (PDF): Dated February 14, 2012, this letter from the ACMD to the UK Home Office likely provides additional advice on the classification of specific steroidal substances.
- “A Change to the Misuse of Drugs Act 1971: control of pipradrol-related compounds and phenazepam”: This source from the UK Home Office, dated June 7, 2012, discusses changes to the Misuse of Drugs Act 1971, specifically addressing the control of pipradrol-related compounds and phenazepam. It may offer insights into the regulation of substances related to 2-(diphenylmethyl)pyrrolidine.